Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 3/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21708260 | 0.92 | KEAP1 (0.47) | KEAP1NFE2L2MAPTTSHRLMNA | |
| SCHEMBL21708315 | 0.89 | KEAP1 (0.36) | KEAP1NFE2L2TP53ALOX5TSHR | |
| SCHEMBL21708216 | 0.87 | KEAP1 (0.39) | KEAP1NFE2L2ALOX5NPC1ALDH1A1 | |
| SCHEMBL21708272 | 0.87 | KEAP1 (0.42) | KEAP1NFE2L2TSHRKMT2A | |
| SCHEMBL21708353 | 0.87 | KEAP1 (0.46) | KEAP1NFE2L2MAPTALDH1A1MEN1 | |
| SCHEMBL21708293 | 0.86 | KEAP1 (0.41) | KEAP1NFE2L2MAPTTSHRHTT | |
| SCHEMBL21708264 | 0.86 | KEAP1 (0.41) | KEAP1NFE2L2MAPTTSHRLMNA | |
| SCHEMBL21708299 | 0.85 | KEAP1 (0.35) | KEAP1NFE2L2MAPTALOX5ALDH1A1 | |
| SCHEMBL21708367 | 0.82 | MMP13 (0.47) | MAPTTSHRALDH1A1L3MBTL1MEN1 | |
| SCHEMBL21734444 | 0.81 | HTR1A (0.41) | KEAP1NFE2L2MAPTTP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210107871-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2021-04-15 | — | — | US | disclosed |
| EP-3611161-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | National University Corporation Hokkaido University (JP) | 2020-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107871-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | FLNA, FLNB, BRI3BP | KEAP1 3844/4885NFE2L2 3888/4885MAPT 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.